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Abstract
Background: Predicting which patients with hip osteoarthritis are more likely to show disease progression is
important for healthcare professionals. Therefore, the aim of this review was to assess which factors are
predictive of progression in patients with hip osteoarthritis.
Methods: A literature search was made up until 14 March 2019. Included were cohort and case-control studies
evaluating the association between factors and progression (either clinical, radiological, or THR). Excluded were studies
with a follow-up < 1 year or specific underlying pathologies of osteoarthritis. Risk of bias was assessed using the QUIPS
tool. A best-evidence synthesis was conducted.
Results: We included 57 articles describing 154 different factors. Of these, a best-evidence synthesis was possible for
103 factors, separately for clinical and radiological progression, and progression to total hip replacement. We found
strong evidence for more clinical progression in patients with comorbidity and more progression to total hip
replacement for a higher Kellgren and Lawrence grade, superior or (supero) lateral femoral head migration, and
subchondral sclerosis. Strong evidence for no association was found regarding clinical progression for gender, social
support, pain medication, quality of life, and limited range of motion of internal rotation or external rotation. Also,
strong evidence for no association was found regarding radiological progression for the markers CTX-I, COMP, NTX-I,
PINP, and PIIINP and regarding progression to total hip replacement for body mass index.
Conclusion: Strong evidence suggested that 4 factors were predictive of progression of hip osteoarthritis, whereas 12
factors were not predictive of progression. Evidence for most of the reported factors was either limited or conflicting.
Protocol registration: PROSPERO, CRD42015010757
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Background
The hip is the third joint most commonly affected by
osteoarthritis (OA) [1]. No therapeutic cure exists for
hip OA. Therefore, predicting which patients with hip
OA are more likely to progress in their disease is of
special interest, particularly if these predictive factors
are potentially modifiable.
In 2002, Lievense et al. published a systematic re-
view in which they identified several predictive factors
for the progression of hip OA [2]. They used a best-
evidence synthesis to draw conclusions about the
available evidence per factor. Strong evidence was
found for more rapid progression in patients with a
superior or superolateral migration of the femoral
head or an atrophic bone response. Conversely, strong
evidence was found for no association between pro-
gression of hip OA and obesity. In 2009, Wright et
al. also reviewed the known prognostic factors and
their quality of evidence [3]. They concluded that
only a few factors are strongly associated with the
progression of hip OA, i.e., age, joint space width, mi-
gration of the femoral head, femoral osteophytes,
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bony sclerosis, Kellgren and Lawrence (K-L) grade 3,
hip pain at baseline, and a Lequesne index score > 10.
In that review, acetabular osteophytes showed no as-
sociation with progression. Furthermore, de Rooij et
al. studied the factors predicting the course of pain
and function. They found strong evidence that higher
comorbidity count and lower vitality predict a wors-
ening of physical function [4]. Although all reviews
described additional predictive factors, the evidence
for these factors was either limited or conflicting.
Since the literature search of Wright et al. (in October
2008) and de Rooij et al. (in July 2015) more research on
prognostic factors of hip OA have been conducted, and
new methods to assess and review prognostic studies
have been developed [5].
Therefore, the aim of this present study was to sys-
tematically review the evidence of patient, health, and
diagnostic variables associated with the progression of
hip OA.
Methods
Search of the literature
A search was made in the databases of Embase,
MEDLINE (OvidSP), Web-of-Science, Cochrane Li-
brary, PubMed publisher, and Google Scholar from
the inception of the database until 14 March 2019,
using the keywords hip, osteoarthritis, and prognosis
(and their synonyms). We excluded congress abstracts
and editorial letters from our search by setting these
as limits to restrain the number of found citations
without losing valuable citations. The reference lists
of relevant articles were screened for additional rele-
vant studies. A complete syntax of the search can be
found in Additional file 1. The process of the search
Fig. 1 Flowchart of the search and selection of studies
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Table 1 Characteristics of the selected studies
Study Design Participants in the
cohort (n)
Assessment of progression Follow-
up
period
Agricola et al.
[11]
Prospective cohort
(CHECK)
1002 (analyzed
723 patients)
THR 5 years
Agricola et al.
[12]
Prospective cohort
(CHECK)
1002 (analyzed
550 women)
THR due to OA 5 years
Agricola et al.
[12]
Nested case-control
(Chingford cohort)
1003 (analyzed
114)
THR due to OA 19 years
Auquier et al.
[13]
Retrospective cohort 131 Increase in stage of pain and function, stages minimal, moderate, moderate-
severe, severe
6–23
years
Barr et al. [14] Case-control 195 (analyzed 102
patients)
THR (compared to non-progression hips: increase of ≤ 1 K-L grade) 5 years
Bastick et al.
[15]
Prospective cohort
(CHECK)
545 (analyzed 363
patients)
NRS score for pain, group moderate progression compared to mild pain.
Groups based on LCGA
5 years
Bastick et al.
[16]
Prospective cohort
(CHECK)
588 (analyzed 538) THR 5 years
Bergink et al.
[17]
Prospective cohort
(Rotterdam I)
176 1. Increase ≥ 1 K-L grade
2. Decrease ≥ 1 mm of joint space
Average
8.4 years
Birn et al. [18] Case-control 94 (5 cases, 89
controls)
Rapidly destructive OA: > 2 mm or > 50% JSN/year NR
Birrell et al. [19] Prospective cohort 195 Time to being put on a waiting list for THR 36
months
Bouyer et al.
[20]
Prospective cohort
(KHOALA)
242 (analyzed 133
patients)
1. Increase ≥ 1 K-L grade
2. Increase ≥ 1 JSN score
3. Time to THR
3 years
Castano
Betancourt et
al. [21]
Prospective cohort
(GOAL)
189 JSN≥ 20% compared to baseline or THR 2 years
Chaganti et al.
[22]
Nested case-control
(SOF)
168 cases and 173
controls
Decrease in MJS of 0.5 mm, increase of ≥ 1 in summary grade, increase ≥ 2 in
total osteophyte score, or THR for OA
Average
8.3 years
Chevalier et al.
[23]
Prospective cohort 30 Rapid evolution: JSN > 0.6 mm/year 1 year
Conrozier et al.
[24]
Case-control 104 (analyzed 10
cases, 23 controls)
Rapidly progressive hip OA: severe hip pain, symptom onset within the last 2
years, annual rate of JSN > 1mm, ESR < 20 mm/h, absence of detectable
inflammatory or crystal-induced joint disease
NR
Conrozier et al.
[25]
Retrospective cohort 89 Radiographic: YMN, calculated from MJS in mm/year 18–300
months
Conrozier et al.
[26]
Prospective cohort 48 JSN in mm/year 1 year
Danielsson [27,
28]
Prospective cohort 168 1. Increase in pain index 0–5
2. Operation because of hip OA
3. Increase in radiographic index 0–10
8–12
years
van Dijk et al.
[29]
Prospective cohort 123 1. Decrease in WOMAC function
2. Increase in seconds of timed walking test
3 years
van Dijk et al.
[30]
Prospective cohort 123 1. Decrease in WOMAC function
2. Increase in seconds of timed walking test
3 years
Dorleijn et al.
[31]
Prospective cohort
(GOAL)
222 (analyzed 111
patients)
VAS score for pain, group highly progressive compared to mild pain groups
based on LCGA
2 years
Dougados et
al. [32]
Prospective cohort
(ECHODIAH)
508 (analyzed 461
patients)
Radiological: ≥ 0.6 mm decrease in JSW 1 year
Dougados et
al. [33]
Prospective cohort
(ECHODIAH)
508 (analyzed 463
patients)
Radiological: > 0.5 mm decrease in JSW 2 years
Dougados et
al. [34]
Prospective cohort 508 Time to the requirement of THR 3 years
Fukushima et Prospective cohort 20 Increase in Tönnis grade 25
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Table 1 Characteristics of the selected studies (Continued)
Study Design Participants in the
cohort (n)
Assessment of progression Follow-
up
period
al. [35] months
Golightly et al.
[36]
Prospective cohort
(Johnston County)
1453 Increase in K-L grade or increase in hip symptoms (mild, moderate, severe) 3–13
years
Gossec et al.
[37]
Prospective cohort 741 (analyzed 505
patients)
THR 2 years
Hartofilakidis et
al. [38]
Retrospective cohort 210 THR 2 to >
10 years
Hawker et al.
[39]
Prospective cohort 2128 Time to THR 6.1 years
Hoeven et al.
[40]
Prospective cohort
(Rotterdam I)
5650 (number
analyzed: NR)
Increase ≥ 1 K-L grade baseline to follow-up 10 years
Holla et al. [41] Prospective cohort
(CHECK)
588 Moving into a higher group (quintiles of WOMAC-PF 0–68) or remaining
within the three highest groups
2 years
Juhakoski et al.
[42]
Prospective cohort 118 1. WOMAC pain (0–100)
2. WOMAC function (0–100)
2 years
Kalyoncu et al.
[43]
Retrolective cohort
(ECHODIAH)
192 THR 10 years
Kelman et al.
[44]
Nested case-control
(SOF)
396 (cases 197,
controls 199)
Decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1 in the
summary grade, an increase of ≥ 2 in total osteophyte score, or THR
8.3 years
Kerkhof et al.
[45]
Prospective cohort
(Rotterdam I)
1610 Radiologic: JSN ≤ 1.0 mm or THR during follow-up NR
Kopec et al.
[46]
Prospective cohort
(Johnston County)
1590 (analyzed
571 people)
Increase ≥ 1 in K-L grade 3–13
years
Lane et al. [47] Prospective cohort
(SOF)
745 Decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1 in the
summary grade, an increase of ≥ 2 in total osteophyte score, or THR
8 years
Lane et al. [48] Nested case-control
(SOF)
342 Radiological: decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1
in the summary grade, an increase of ≥ 2 in total osteophyte score, or THR
8.3 years
Laslett et al.
[49]
Prospective cohort
(TasOAC)
1099 (analyzed
765 people)
WOMAC pain (0–100) 2–4
years
Ledingham
1993 [50]
Prospective cohort 136 1. Global assessment of radiographic change
2. THR
3–73
months
Lievense et al.
[51]
Prospective cohort 224 (analyzed 163
patients)
THR 5.8 years
Maillefert et al.
[52]
Prospective cohort
(ECHODIAH)
508 1. Decrease in JSW > 50% during the first year follow-up
2. THR in 1–5 years of follow-up
5 years
Mazieres et al.
[53]
Prospective cohort
(ECHODIAH)
507 (analyzed 333
patients)
JSN≥ 0.5 mm or THP 3 years
Nelson et al.
[54]
Prospective cohort
(Johnston County)
309 1. Increase in K-L grade
2. Increase in osteophyte severity grade
3. Increase in JSN severity grade
5 years
Perry et al. [55] Case-control 44 Radiographic: progressive deterioration 5–14
years
Peters et al.
[56]
Prospective cohort 587 (analyzed 214
patients)
New Zealand score 0–80 (combination of pain and function) 7 years
Pisters et al.
[57]
Prospective cohort 149 Increase in WOMAC function on average over time (measured at 1, 2, 3, 5
years)
5 years
Pollard 201et
al. 2 [58]
Prospective cohort 264 Signs on examination of hip OA or symptoms at baseline and signs and
symptoms at follow-up
5 years
Reijman et al.
[59]
Prospective cohort
(Rotterdam I)
1235 JSN≥ 1.0 mm in at least 1 of 3 compartments (lateral, superior, axial) 6.6 years
Reijman et al.
[60]
Prospective cohort
(Rotterdam I)
1904 Radiologic: JSN ≤ 1.0 mm or THR during follow-up 6.6 years
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was assisted and partly conducted by an experienced
medical librarian.
Criteria for selection of studies
The following are the criteria for the selection of studies:
1) The study should investigate the factors associated
with the progression of hip OA.
2) The article was written in English, Dutch, German,
French, Spanish, Italian, Danish, Norwegian, or
Swedish. These languages were sufficiently
mastered by at least two reviewers.
3) The article was available in full text.
4) Patients in the study reported complaints like pain,
disability, or stiffness of the hip, suspected or
confirmed (radiographic or clinical criteria) to
originate from OA of the hip.
5) The study design was a cohort or a case-control
study or a randomized controlled trial in which
the estimation of the prognostic factor was
adjusted for the intervention or only investigated
in the control group.
6) Progression was determined radiographically or
clinically. Radiographic progression could be
determined by, for example, X-ray or MRI.
Examples of clinical progression were worsening of
pain or function or reaching the point of indication
for total hip replacement (THR).
7) Follow-up should be at least 1 year (based on the
recommendations for measuring structural
progression [6]).
8) The study was excluded if the population under
investigation had a specific underlying pathology,
such as trauma (fractures), infection, rheumatoid
arthritis, ankylosing spondylitis, Perthes’ disease,
tuberculosis, hemochromatosis, sickle cell disease,
Cushing’s syndrome, and femoral head necrosis.
Selection of studies
CHT screened all the titles and abstracts and ex-
cluded articles that did not investigate patients with
OA of the hip. Secondly, CHT and PAJL independ-
ently selected the titles and abstracts using the selec-
tion criteria to decide which articles required the
retrieval of full text; in case of disagreement, the full
text was retrieved. Then, all full texts were independ-
ently assessed by CHT and PAJL to include all rele-
vant studies according to the selection criteria. In
case of disagreement and both reviewers were unable
to reach consensus, SMABZ made the final decision.
Data extraction
Information on the design, setting, study population
(e.g., recruitment period, age, gender, definition of hip
OA), number of participants, follow-up period, loss to
follow-up, prognostic factors, assessment of progres-
sion, outcomes, and strength of association were ex-
tracted using standardized forms by CHT and
checked by PAJL.
Prognostic factors were divided into patient vari-
ables, disease characteristics, and chemical or imaging
markers. Outcomes were divided into clinical progres-
sion, radiographic progression, or (indication for) re-
ceiving a THR.
If outcomes were measured at several follow-up
moments, all moments were extracted. After the col-
lection of all data, the follow-up moments that were
Table 1 Characteristics of the selected studies (Continued)
Study Design Participants in the
cohort (n)
Assessment of progression Follow-
up
period
Reijman et al.
[61]
Prospective cohort
(Rotterdam I)
1676 1. JSN of ≥ 1 mm
2. JSN of ≥ 1.5 mm
3. Increase of ≥ 1 K-L grade
6.6 years
Solignac [62] Prospective cohort
(ECHODIAH)
507 (analyzed 333
patients)
JSN≥ 0.5 mm or THP 3 years
van Spil et al.
[63]
Prospective cohort
(CHECK)
1002 (analyzed
178 patients)
Radiographic: ≥ 1 K-L grade increase 5 years
Thompson et
al. [64]
Case-control 34 cases, controls:
NR
Rapidly progressive OA: loss of bone or a combined loss of bone and articular
cartilage at rate > 5mm per year
18
months
Tron et al. [65] Retrospective cohort 39 Mean annual JSN in mm NR
Verkleij et al.
[66]
Prospective cohort
(GOAL)
222 (analyzed 111
patients)
VAS score for pain, group highly progressive compared to mild pain, groups
based on LCGA
2 years
Vinciguerra et
al. [67]
Retrospective cohort 149 Time to THR Variable
NR not reported, OA osteoarthritis THR total hip replacement, K-L grade Kellgren and Lawrence grade, MJS minimum joint space, JSN joint space narrowing, JSW
joint space width, YMN yearly mean narrowing, LCGA latent class growth analysis, ESR erythrocyte sedimentation rate, NRS numeric rating scale, VAS visual
analog scale
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Table 2 Risk of bias assessment summary (QUIPS)
Study Study
participation
Study
attrition
Prognostic factor
measurement
Outcome
measurement
Study
confounding
Statistical analysis and
reporting
Agricola et al. [11] Low Low Moderate Low Low Low
Agricola et al. [12] Low Low Moderate Low Moderate Low
Auquier et al. [13] Moderate Moderate Low Moderate High Moderate
Bastick et al. [15] Low Low Low Low Low Low
Bastick et al. [16] Low Low Low Low Low Low
Bergink et al. [17] Low Moderate Moderate Low Low Moderate
Bouyer et al. [20] Low High Moderate Moderate Low Low
Birrell et al. [19] Low Low Moderate Low Low Low
Castano Betancourt et
al. [21]
Low Low Low Low Low Low
Chaganti et al. [22] Low Low Low Low Moderate Low
Chevalier et al. [23] Moderate Low Low Low Moderate Moderate
Conrozier et al. [25] Moderate Low Low Low Low Low
Conrozier et al. [26] Moderate Low Low Low Low Low
Danielsson [27, 28] Low High High High High High
van Dijk et al. [29] Low Low Low Low Low Low
van Dijk et al. [30] Low Low Low Low Low Low
Dorleijn 2015 [31] Low Low Moderate Low Moderate Low
Dougados et al. [32] Low Low Low Low Low Low
Dougados et al. [33] Low Low Low Moderate High Moderate
Dougados et al. [34] Low Low Low Low Low Low
Fukushima et al. [35] Moderate Low Low High High Low
Golightly et al. [36] Low Moderate Low Low Low Low
Gossec et al. [37] Low Low Low Low Low Low
Hartofilakidis et al. [38] Moderate Moderate Moderate Moderate High High
Hawker et al. [39] Moderate Low Low Low Low Low
Hoeven et a. [40] Low Moderate Low Low Low Low
Holla et al. [41] Low Low Low Low Low Low
Juhakoski et al. [42] Low Low Low Moderate Low Low
Kalyoncu et al. [43] Low Low Moderate Moderate Low Low
Kelman et al. [44] Low Low Low Low Low Low
Kerkhof et al. [45] Low Moderate Moderate Low Low Low
Kopec et al. [46] Low Moderate Low Low Low Low
Lane et al. [47] Low Low Low Low Low Low
Lane et al. [48] Moderate Low Moderate Low Low Low
Laslett et al. [49] Low Low Low Low Low Low
Ledingham et al. [50] Moderate Moderate Moderate High High High
Lievense et al. [51] Low Low Moderate Low Low Low
Maillefert et al. [52] Low Low Low Moderate Moderate Moderate
Mazieres et al. [53] Low Low Low Low Low Low
Nelson et al. [54] Low Moderate Low Low Low Low
Peters et al. [56] Low Moderate Moderate Low Moderate Low
Pisters et al. [57] Low Low Low Low Low Low
Pollard et al. [58] Low Low Low Moderate Low Low
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in the closest range to each other were used for the
evidence synthesis.
Risk of bias assessment
The quality of all included cohort studies was evalu-
ated using the QUIPS tool [5, 7]. Studies were
assessed on six domains: study participation, study at-
trition, prognostic factor measurement, outcome
measurement, study confounding, and statistical ana-
lysis and reporting. An overview of all domains and
their items is presented in Additional file 2. Each
study was independently scored by CHT and by a
second reviewer (DMJD, SMABZ, PKB, JBMRO, or
PAJL). In case of disagreement, they attempted to
reach consensus; if this failed, a third reviewer
(JBMRO or PAJL) made the final decision.
Evidence synthesis
A meta-analysis was considered if clinical heterogen-
eity was low, with respect to the study population,
the risk of bias, and the definition of prognostic fac-
tors and defined hip OA progression. In case of a
meta-analysis, an adjusted GRADE assessment for
prognostic research was used to determine the
strength of the evidence [8].
If the level of heterogeneity of the studies was high,
we refrained from pooling in the main analysis and
performed a qualitative evidence synthesis. Associa-
tions were categorized as positive, negative, or no as-
sociation. Ranking of the levels of evidence was based
on Lievense et al. [2] and Davis et al. [9]:
1) Strong evidence: consistent findings (≥ 75% of the
studies showing the same direction of the
association) in two or more studies with a low risk
of bias in all domains of the QUIPS tool
2) Moderate evidence: consistent findings in more
than two studies with a moderate or high risk of
bias in one or more domains of the QUIPS tool or
consistent findings in two studies, of which one
study has a low risk of bias in all domains of the
QUIPS tool
3) Limited evidence: one study with a low risk of bias
in all domains of the QUIPS tool or two studies
with a moderate or high risk of bias in one or more
domains of the QUIPS tool
4) Conflicting evidence: < 75% of the studies showing
the same direction of the association
If a prognostic factor was described in two different
articles that investigated the same study cohort and out-
come of progression, one study was selected to include
in the evidence synthesis. In this case, we selected the
article according to a decision tree: (1) lowest risk of
bias, (2) prognostic factor is the primary outcome of the
study, and (3) the largest number of participants.
Post hoc changes to the study protocol
After contact with one of the developers of the
QUIPS tool, we learned that it is not validated to
judge the risk of bias of case-control studies and
would probably not adequately take into account the
higher risk of recall bias and the selection bias of
case-control studies. Therefore, we decided to exclude
case-control studies from our evidence synthesis, ex-
cept for nested case-control studies. Nested case-con-
trol studies are less prone to selection and recall bias
because of the underlying known cohort [10], which
can be judged using the QUIPS tool.
Results
Included studies
The initial search yielded 6429 citations of which 57 arti-
cles were finally included. Figure 1 shows the reasons for
the study exclusion, and Table 1 presents a brief over-
view of the characteristics of the 57 included studies (a
Table 2 Risk of bias assessment summary (QUIPS) (Continued)
Study Study
participation
Study
attrition
Prognostic factor
measurement
Outcome
measurement
Study
confounding
Statistical analysis and
reporting
Reijman et al. [59] Low Moderate Low Low Low Low
Reijman et al. [60] Low Moderate Low Low Low Low
Reijman et al. [61] Low Moderate Low Low Low Low
Solignac [62] Low Low Low Low Moderate Low
van Spil et al. [63] Low Low Low Low Low Low
Tron et al. [65] High High High Moderate High Moderate
Verkleij et al. [66] Low Low Low Low Moderate Low
Vinciguerra et al. [67] Low Moderate High Low High High
Studies with a low risk of bias in all domains are presented in italics
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Table 3 Factors predicting (indication for) total hip replacement (THR)
Prognostic
factor
Studies Associations Best-evidence synthesis
Patient variables
No association
Body mass index Strong evidence for no association
2 low risk of bias cohorts [16, 37]
5 cohorts [20, 39, 50, 51, 67]
No, no
No, no, no, negative,
positive
Female Moderate evidence for no association
3 low risk of bias cohorts [16, 34,
37]
5 cohorts [20, 39, 50–52]
No, positive, no
No, no, no, no, no
Lower educational level Moderate evidence for no association
1 low risk of bias cohort [16]
1 cohort [39]
No
No
Western or White ethnicity Moderate evidence for no association
1 low risk of bias cohort [16]
1 cohort [39]
No
No
Alcohol consumption Limited evidence for no association
1 low risk of bias cohort [16] No
Conflicting evidence
Higher age at baseline Conflicting evidence
3 low risk of bias cohorts [16, 34,
37]
5 cohorts [20, 39, 50, 51, 67]
No, positive,no
No, positive$, no, no,
positive
Disease characteristics
Faster or more progression
Lower global assessment (self-reported) at baseline Moderate evidence for faster or more progression
1 low risk of bias cohort [37]
2 cohorts [39, 50]
Positive
Positive, positive
Previous use of NSAIDs Limited evidence for more progression
1 low risk of bias cohort [37] Positive
No association
Longer duration of symptoms at baseline Moderate evidence for no association
1 low risk of bias cohort [37]
1 cohort [19]
No
No
Having another disease (comorbidity) Moderate evidence for no association
1 low risk of bias cohort [16]
1 cohort [39]
No
No
Morning stiffness Moderate evidence for no association
1 low risk of bias cohort [16]
1 cohort [51]
No
No
Use of pain medication at baseline Moderate evidence for no association
1 low risk of bias cohort [16]
1 cohort [19]
No
No
Presence of Heberden’s or Bouchard’s nodes Moderate evidence for no association
1 low risk of bias cohort [16]
2 cohorts [50, 51]
No
No, no
Previous intra-articular injection in the hip Limited evidence for no association
1 low risk of bias cohort [37] No
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Table 3 Factors predicting (indication for) total hip replacement (THR) (Continued)
Prognostic
factor
Studies Associations Best-evidence synthesis
Conflicting evidence
More limitations in physical function at baseline Conflicting evidence
3 low risk of bias cohorts [16, 34,
37]
2 cohorts [19, 39]
Positive, positive, no
No, no
More pain at baseline Conflicting evidence
3 low risk of bias cohorts [16, 34,
37]
4 cohorts [19, 39, 50, 51]
Conflicted$$, positive,
positive
Positive, no, positive, no
Painful hip flexion (active or passive) Conflicting evidence
1 low risk of bias cohort [16]
1 cohort [51]
Positive
No
Painful hip internal rotation (active or passive) Conflicting evidence
1 low risk of bias cohort [16]
1 cohort [51]
Positive
No
Night pain at baseline Conflicting evidence
2 cohorts [50, 51] Positive, no
Limited range of motion of flexion of the hip Conflicting evidence
1 low risk of bias cohort [16]
2 cohorts [19, 51]
Positive
Positive, no
Limited range of motion of internal hip rotation Conflicting evidence
1 low risk of bias cohort [16]
2 cohorts [19, 51]
Positive
Positive, no
Limited range of motion of external hip rotation Conflicting evidence
2 cohorts [19, 51] Positive, no
Chemical or imaging markers
Faster or more progression
Higher K-L grade at baseline Strong evidence for more or faster progression
2 low risk of bias cohorts [34, 37]
1 cohorts [51]
Positive, positive
Positive
Superior or superolateral migration of the femoral head Strong evidence for more or faster progression
2 low risk of bias cohorts [34, 47]
1 cohort [38]
Positive, positive
Positive
Subchondral sclerosis Strong evidence for more progression
2 low risk of bias cohorts [16, 47] Positive, positive
Statistical shape modeling Moderate evidence that certain modes of SSM can predict
progression
3 cohorts [11, 12, 12] Positive, positive, positive
Joint space narrowing at baseline Moderate evidence for more or faster progression
1 low risk of bias cohort [16]
1 cohort [67]
Positive
Positive
No association
Cam-type deformity (alpha angle > 60°) Limited evidence for no association
1 low risk of bias cohort [16] No
Conflicting evidence
Erythrocyte sedimentation rate Conflicting evidence
1 low risk of bias cohort [16]
1 cohort [51]
Positive
No
Atrophic bone response (no osteophytes present) Conflicting evidence
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more extensive overview is available in Additional file 3).
Of the 57 studies, 48 were cohort studies (37 with a pro-
spective design), 4 were nested case-control studies, and
5 were case-control studies. These last 5 studies were ex-
cluded from the evidence synthesis for the reasons men-
tioned above.
Risk of bias assessment
In 68% of all assessed domains from all studies, there
was an immediate consensus between the reviewers
(Cohen’s kappa 0.375, linear weighted kappa 0.484).
In 9 assessments of a domain (3%) in 6 different
studies, a third reviewer made the final judgment. In
total, 15 studies scored a low risk of bias in all do-
mains [15, 16, 21, 29, 30, 32, 34, 37, 41, 44, 47, 49,
53, 57, 63] (Table 2).
Prognostic factors
We identified 154 possible prognostic factors: 23 pa-
tient variables, 77 disease characteristics, and 54
chemical markers or imaging markers. Fifty-one fac-
tors were only investigated once in a single cohort or
study (not a low risk of bias study) and could not be
included in the evidence synthesis. An overview of all
the results and risk of bias assessment of the studies
describing these factors is presented in Add-
itional file 4. The remaining 103 factors were in-
cluded in the evidence synthesis. To decrease
heterogeneity, evidence synthesis was done separately
per group of outcomes (radiological progression, clin-
ical progression, or THR). However, heterogeneity
was still considered high in each outcome group,
mainly within respect to the definition of the prog-
nostic factor, progression, and measure of the associ-
ation. Therefore, we refrained from pooling and
performed a best-evidence synthesis. If a factor could
not be subdivided because it was described by two or
three studies that used a definition of progression, all
in a separate group of outcome, we combined the
groups of outcomes. The results of these factors are
presented in Additional file 5.
Evidence for factors predicting progression
Strong evidence was found for a higher K-L grade at
baseline, superior or (supero) lateral femoral head mi-
gration, and subchondral sclerosis to be predictive of
faster progression to THR or more patients progressing
to THR. Body mass index was found not to be predict-
ive of faster or more progression to THR (Table 3).
Strong evidence was found for no association be-
tween radiological progression and the following
markers: C-terminal telopeptide of collagen type I
(CTX-I), cartilage oligomeric matrix protein (COMP),
N-terminal telopeptide of collagen type I (NTX-I),
and N-terminal propeptide of procollagen type I and
type III (PINP, PIIINP) (Table 4).
Strong evidence showed comorbidity to be predict-
ive of clinical progression. On the other hand, gender,
social support, use of pain medication at baseline,
quality of life at baseline, and limited range of motion
of internal hip rotation or external hip rotation were
not predictive of clinical progression (Table 5).
For other factors, only moderate, limited, or conflict-
ing evidence was found for predicting or not predicting
progression (Tables 3, 4, and 5).
Discussion
In this study, we systematically reviewed all 154 fac-
tors predictive of progression of hip OA, reported in
57 studies. Compared to earlier reviews, there was a
considerable amount of additional evidence available
for the factors previously reported in reviews, as well
as evidence for factors not earlier described.
In this review, some results had changed compared
to the review of Lievense et al. in 2002 [2]. Firstly,
because of the new evidence emerging from the later
studies, especially studies with a clinical outcome of
progression. Secondly, because we used a different
Table 3 Factors predicting (indication for) total hip replacement (THR) (Continued)
Prognostic
factor
Studies Associations Best-evidence synthesis
1 low risk of bias cohort [16]
2 cohorts [50, 51]
Positive
Positive, no
Decrease in joint space width at baseline Conflicting evidence
1 low risk of bias cohort [34]
1 cohort [51]
Positive
No
Wiberg’s center edge angle (CEA) Conflicting evidence
1 low risk of bias cohort [16]
1 cohort [20]
Negative
No
$Exception: age ≥ 82 years showed a negative association with progression, compared to age ≤ 62 years
$$Pain at baseline measured with NRS past week showed a statistically significant positive association with THR; pain at baseline measured with WOMAC pain
showed no statistically significant association with THR
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Table 4 Factors predicting radiological progression
Prognostic factor Studies Associations Best-evidence synthesis
Patient variables
No association
Family history of OA Moderate evidence for no association
3 cohorts [25, 60, 65] No, no, no
Body mass index Moderate evidence for no association
4 cohorts [25, 50, 61, 65] No, no, no, no
Conflicting evidence
Higher age at baseline or at first symptoms Conflicting evidence
1 low risk of bias cohort [32]
4 cohorts [35, 50, 60, 65]
Positive
No, positive, positive, no
Female Conflicting evidence
1 low risk of bias cohort [32]
6 cohorts [25, 27, 35, 50, 60, 65]
Positive
No, no, no, no, positive, no
Disease characteristics
Faster or more progression
More limitations in physical function at baseline Moderate evidence for more progression
1 low risk of bias cohort [32]
1 cohort [60]
Positive
Positive
Hip pain present at baseline or on most days for a least 1 month in the past year Moderate evidence for more progression
1 low risk of bias cohort [47]
1 cohort [60]
Positive
Positive
No association
Forestier’s disease Moderate evidence for no association
3 cohorts [25, 50, 65] No, no, no
Diabetes mellitus Limited evidence for no association
2 cohorts [25, 60] No, no
Bilateral hip OA Limited evidence for no association
2 cohorts [25, 65] No, no
Generalized OA Limited evidence for no association
2 cohorts [25, 65] No, no
Chemical or imaging markers
Faster or more progression
Subchondral sclerosis Moderate evidence for more progression
1 low risk of bias cohort [47]
1 cohort [33]
Positive
Positive
Neck width of the femoral head Limited evidence for more progression
1 low risk of bias cohort [21] Positive
Osteocalcin (OC) Limited evidence for less progression
1 low risk of bias cohort [63] Negative
No association
C-terminal telopeptide of collagen type I (CTX-I) Strong evidence for no association
2 low risk of bias cohorts [53, 63] No, no
Cartilage oligomeric matrix protein (COMP) Strong evidence for no association
3 low risk of bias cohorts [44, 53, 63]
1 cohort [26]
No, no, no
Positive
N-terminal telopeptide of collagen type I (NTX-I) Strong evidence for no association
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Table 4 Factors predicting radiological progression (Continued)
Prognostic factor Studies Associations Best-evidence synthesis
2 low risk of bias cohorts [44, 63] No, no
N-terminal propeptide of procollagen type I (PINP) Strong evidence for no association
2 low risk of bias cohorts [53, 63] No, no
N-terminal propeptide of procollagen type III (PIIINP) Strong evidence for no association
2 low risk of bias cohorts [53, 63] No, no
High-sensitive C-reactive protein (hs-CRP) Moderate evidence for no association
1 low risk of bias cohort [53]
1 cohort [45]
No
No
Angle of the femoral head Moderate evidence for no association
1 low risk of bias cohort [21]
2 cohorts [20, 65]
No
No, no
Acetabular osteophytes only Moderate evidence for no association
1 low risk of bias cohort [47]
1 cohort [33]
No
No
N-terminal propeptide of procollagen type IIA (PIIANP) Limited evidence for no association
1 low risk of bias cohort [63] No
Chondroitin sulphate 846 (CS846) Limited evidence for no association
1 low risk of bias cohort [63] No
Cartilage glycoprotein 40 (YKL-40) Limited evidence for no association
1 low risk of bias cohort [53] No
Matrix metalloproteinases (MMP-1) Limited evidence for no association
1 low risk of bias cohort [53] No
Matrix metalloproteinases (MMP-3) Limited evidence for no association
1 low risk of bias cohort [53] No
Neck length of the femoral head Limited evidence for no association
1 low risk of bias cohort [21] No
Conflicting evidence
Bone mineral content Conflicting evidence
1 low risk of bias cohort [21] Conflicted$
Area/size of the hip joint Conflicting evidence
1 low risk of bias cohort [21] Conflicted$$
C-terminal telopeptide of collagen type II (CTX-II) Conflicting evidence
2 low risk of bias cohorts [53, 63]
1 cohort [59]
Positive, no
Positive
Hyaluronic acid (HA) Conflicting evidence
2 low risk of bias cohorts [53, 63]
1 cohort [23]
Positive, no
No
Atrophic bone response (no osteophytes present) Conflicting evidence
1 low risk of bias cohort [47]
3 cohorts [25, 50, 65]
No
Positive, positive, no
Subchondral cysts Conflicting evidence
1 low risk of bias cohort [47]
1 cohort [33]
Positive
No
Decrease in joint space width at baseline Conflicting evidence
1 low risk of bias cohort [32]
2 cohorts [25, 60]
Positive
No, positive
Superior or (supero) lateral migration of the femoral head Conflicting evidence
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method to assess the risk of bias, some studies were
no longer considered to have a low risk of bias. The
QUIPS tool seems to apply stricter criteria than the
method used by Lievense et al. in 2002. Thirdly, we
divided the outcomes into three different groups of
progression. Thus, due to these methodological differ-
ences (together with additional studies), we were un-
able to confirm an atrophic bone response as a
predictor for radiological progression or progression
to THR. On the other, we were able to confirm their
conclusion on BMI as not predictive of progression
and faster progression in patients with a superolateral
migration of the femoral head.
Most of the prognostic factors reported by Wright
et al. in 2009 [3] were confirmed in this present re-
view in one or more of the outcome groups. The dif-
ferences found in age, femoral and acetabular
osteophytes, and hip pain at baseline were (as with
Lievense et al.) a combination of new evidence, differ-
ences in the risk of bias assessment, and the division
into defined groups of progression. The study from
de Rooij et al. in 2016 [4] reviewed the evidence for
predictors of the course of pain and function and
found comorbidity and vitality (SF-36) to be predict-
ive of function, as we found for clinical progression.
However, although they also used the QUIPS tool to
assess the risk of bias, they used a different cutoff
point to classify a study as having a low risk of bias.
Therefore, some earlier findings of strong evidence
for no association with the course of pain or function
were confirmed as only moderate evidence for no as-
sociation with clinical progression in our review.
Other differences between this review and the present
one are mainly attributable to the differences in the
selection criteria. In Table 6, we summarized all
factors with strong evidence to be predictive of pro-
gression found in one of these four reviews and the
overlap and differences in evidence for these factors.
Strengths of this present review are the sensitive lit-
erature search and our systematic approach to the se-
lection, risk of bias assessment, and the best-evidence
synthesis. Therefore, we have presented an extensive
overview of reported prognostic factors and existing
evidence for their associations. In performing the evi-
dence synthesis divided into outcome (radiological,
clinical, or THR), we decreased the heterogeneity and
we believe the results to be more accurate for daily
practice. Unfortunately, heterogeneity was still too
high to perform a meta-analysis. Therefore, we were
bound to a best-evidence synthesis and unable to cal-
culate the strengths of the associations. This limits
the translation to the daily clinical practice. Another
disadvantage of this synthesis compared to a meta-
analysis is that smaller studies contribute to the result
with the same weight as larger studies, even though
the smaller studies may have low power to show a
statistically significant association.
In the selection of studies, several restrictions were
imposed. First, languages were restricted to ensure
that at least two researchers had a reasonable under-
standing of the languages included so all articles were
reliably assessed. However, this implies that we may
have missed studies from countries in which publica-
tion in English is less common. Secondly, negative re-
sults (i.e., no association was found) are less likely to
be published and are therefore not well represented
in this review.
We used the QUIPS tool to assess the risk of bias.
Nine other studies using this tool reported an inter-
rater agreement ranging from 70 to 89.5% (median
Table 4 Factors predicting radiological progression (Continued)
Prognostic factor Studies Associations Best-evidence synthesis
2 low risk of bias cohorts [32, 47]
2 cohorts [25, 50]
Positive, no
No, positive
Higher K-L grade at baseline Conflicting evidence
4 cohorts [33, 50, 60, 65] No, positive, positive, no
Acetabular index (Horizontal toit externe angle) Conflicting evidence
2 cohorts [20, 65] Conflicted$$$, no
Wiberg’s center edge angle (CEA) Conflicting evidence
2 cohorts [20, 65] No, negative
$BMC of superior (p = 0.009) and medial (p = 0.019) quart femoral head, arc regions 2–4 (p = 0.02, 0.001, 0.003, respectively), and the acetabular arc was higher in
patients with progression than without progression. BMC of the femoral neck (p = 0.17), intertrochanteric area (p = 0.9), trochanteric area (p = 0.6), and inferior (p =
0.08) and lateral (p = 0.06) quart femoral head and arc region 1 (p = 0.19) of acetabular arc was not significantly different between patients with or
without progression
$$The area/size of superior (p = 0.002), medial (p = 0.002), inferior (p = 0.003), and lateral (p = 0.003) femoral head and of arc regions 2–4 (p = 0.007, 0.001 and 0.005
respectively) of acetabular arc was higher in patients with progression than without progression. The area/size of the femoral neck (p = 0.6), intertrochanteric area
(p = 0.16), trochanteric area (p = 0.4), and arc region 1 (p = 0.2) of the acetabular arc was not significantly different between patients with progression and
without progression.
$$$A statistically significant association was found between the acetabular index and progression defined as ≥ 1 increase in joint space narrowing; however, no
statistically significant association was found between the acetabular index and progression defined as ≥ 1 increase in K-L grade
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Table 5 Factors predicting clinical progression
Prognostic factor Studies Associations Best-evidence synthesis
Patient variables
No association
Female Strong evidence for no association
2 low risk of bias cohorts [41, 57]
5 cohorts [13, 27, 42, 56, 66]
No, no
Positive, no, no, no, no
Social support Strong evidence for no association
2 low risk of bias cohorts [41, 57] No, no
Higher age at baseline Moderate evidence for no association
1 low risk of bias cohort [41, 57]
3 cohorts [42, 56, 66]
No, positive
No, no, no
Paid employment Moderate evidence for no association
1 low risk of bias cohort [41]
2 cohorts [42, 56]
No
No, no
Living alone Moderate evidence for no association
1 low risk of bias cohort [41]
1 cohort [30]
No
No
Alcohol consumption Limited evidence for no association
1 low risk of bias cohort [41] No
Conflicting evidence
Physical activity during leisure Conflicting evidence
1 low risk of bias cohort [41] Conflicted$
Body mass index Conflicting evidence
2 low risk of bias cohorts [41, 57]
3 cohorts [42, 56, 66]
Positive, no
No, no, positive
Lower education level Conflicting evidence
2 low risk of bias cohorts [41, 57]
2 cohorts [42, 66]
No, negative
Positive, no
Disease characteristics
Faster or more progression
Having another disease (comorbidity) Strong evidence for more progression
2 low risk of bias cohorts [41, 57]
1 cohort [42]
Positive$$, positive
Positive
Concurrent morning stiffness of the knee (< 30min) Limited evidence for more progression
1 low risk of bias cohort [41] Positive
No association
Use of (pain) medication at baseline Strong evidence for no association
2 low risk of bias cohorts [29, 41] No, no
Quality of life at baseline Strong evidence for no association
2 low risk of bias cohort [30, 41] No$$$, no
Limited range of motion of internal hip rotation Strong evidence for no association
2 low risk of bias cohorts [41, 57]
1 cohort [66]
No, no
No
Limited range of motion of external hip rotation Strong evidence for no association
2 low risk of bias cohorts [15, 57] No, no
Concurrent knee pain Moderate evidence for no association
1 low risk of bias cohort [41]
1 cohort [66]
No
No
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Table 5 Factors predicting clinical progression (Continued)
Prognostic factor Studies Associations Best-evidence synthesis
Depression Moderate evidence for no association
1 low risk of bias cohort [41]
1 cohort [56]
No
No
Way of coping Moderate evidence for no association
1 low risk of bias cohort [41]
1 cohort [30]
No
No
Respiratory comorbidity Moderate evidence for no association
1 low risk of bias cohort [29]
1 cohort [56]
No
No
Patient-rated health Limited evidence for no association
1 low risk of bias cohort [41] No
Cardiac comorbidity (cumulative illness rating scale 1, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Vascular comorbidity (cumulative illness rating scale 2, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Eye, ear, nose, throat, and larynx diseases (cumulative illness rating scale 4, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Upper gastrointestinal comorbidity (cumulative illness rating scale 5, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Lower gastrointestinal comorbidity (cumulative illness rating scale 6, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Hepatic comorbidity (cumulative illness rating scale 7, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Renal comorbidity (cumulative illness rating scale 8, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Other genitourinary comorbidities (cumulative illness rating scale 9, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Neurological comorbidity (cumulative illness rating scale 11, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Psychiatric comorbidity (cumulative illness rating scale 12, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Comorbidity of endocrine and metabolic diseases (cumulative illness rating scale 13, severity score ≥ 2) Limited evidence for no association
1 low risk of bias cohort [29] No
Cognitive functioning Limited evidence for no association
1 low risk of bias cohort [57] No
Muscle strength hip abduction Limited evidence for no association
1 low risk of bias cohort [57] No
Pain during sitting or lying Limited evidence for no association
1 low risk of bias cohort [41] No
Joint stiffness (WOMAC) Limited evidence for no association
1 low risk of bias cohort [15] No
Use of additional supplements or vitamins Limited evidence for no association
1 low risk of bias cohort [15] No
Concurrent pain during flexion of ipsilateral knee Limited evidence for no association
1 low risk of bias cohort [15] No
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83.5%) and a kappa statistic ranging from 0.56 to 0.82
(median 0.75) [7]. Compared to these data, our inter-
rater agreement was low and considered to be moder-
ate. Disagreement was mainly due to the differences
in interpretation of items of the QUIPS tool; however,
only for very few items, a third reviewer was needed
to make a final decision.
Hip dysplasia and femoral acetabular impingement
were initially considered to be underlying pathologies
and were excluded from this analysis. However, the
range of severity of these morphologies is substantial,
i.e., some of these morphologies should clearly be
considered as an underlying pathology, whereas others
are more subtle and sometimes undiagnosed. These
subtle morphologies might be considered to be pos-
sible prognostic factors, rather than underlying path-
ologies. Therefore, all citations were screened using
the terms “hip dysplasia” and “femoral acetabular im-
pingement” in the title or abstract. However, we
found only one small study [35] which investigated
the radiographic findings of femoral acetabular im-
pingement as a prognostic factor (results of this study
are included in Additional file 4). In the studies
already included, three studies did not specifically in-
clude patients with hip dysplasia or femoral acetabu-
lar impingement but did investigate the associated
angles (Wiberg’s center edge angle and alpha angle,
respectively). Since the evidence for these associations
with the progression of hip OA was weak, future
studies and reviews should investigate these morph-
ologies as possible prognostic factors.
Conclusion
We conclude that there is consistent evidence that
four factors (comorbidity, K-L grade, superior or
(supero) lateral femoral head migration, and subchon-
dral sclerosis) were predictive of progression of hip
OA, whereas 12 factors were not predictive. The
Table 5 Factors predicting clinical progression (Continued)
Prognostic factor Studies Associations Best-evidence synthesis
Knee flexion Limited evidence for no association
1 low risk of bias cohort [29] No
Knee extension Limited evidence for no association
1 low risk of bias cohort [29] No
Strength of isometric knee extension Limited evidence for no association
1 low risk of bias cohort [29] No
Conflicting evidence
Bilateral hip OA Conflicting evidence
1 low risk of bias cohort [41]
1 cohort [66]
Positive, if equal symptoms
No
Pain at baseline (self-reported or during physical examination) Conflicting evidence
3 low risk of bias cohorts [29, 41, 47] No, no, positive
Longer duration of symptoms at baseline Conflicting evidence
1 low risk of bias cohort [57]
2 cohorts [42, 66]
No
No, positive
Morning stiffness Conflicting evidence
1 low risk of bias cohort [41]
1 cohort [66]
No
Positive
Limited range of motion of flexion of the hip Conflicting evidence
2 low risk of bias cohorts [41, 57]
1 cohort [66]
Positive, no
No
Chemical or imaging markers
Conflicting evidence
Higher K-L grade at baseline Conflicting evidence
1 low risk of bias cohort [12]
2 cohorts [42, 66]
No
No, positive
$Patients who were 3–5 days/week physically active in their leisure time showed less progression than patients who were 0–2 days/week physically active in their
leisure time. No difference was found between patients spending 6–7 days/week on physical activity and patients spending 0–2 days/week on physical activity
$$≥ 3 more diseases compared to no comorbidities
$$$Subscale of SF-36 vitality showed a positive association with WOMAC function score
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evidence for other factors was weak or conflicting. Health
professionals caring for patients with hip OA will benefit
from the insight in prognostic factors, e.g., patients more
likely to progress rapidly may need an intensified symp-
tomatic treatment or early referral to an orthopedic sur-
geon. For this, we still need more high-quality research
focusing on the prognostic factors in hip OA.
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CS846: Chondroitin sulphate 846; CTX-I: C-terminal telopeptide of collagen
type I; CTX-III: C-terminal telopeptide of collagen type II; ESR: Erythrocyte
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Development and Evaluation; HA: Hyaluronic acid; hs-CRP: High-sensitive C-
reactive protein; JSN: Joint space narrowing; JSW: Joint space width; K-L
grade: Kellgren and Lawrence grade; LCGA: Latent class growth analysis;
MJS: Minimum joint space; MMP-1: Matrix metalloproteinases-1; MMP-
3: Matrix metalloproteinases-3; MRI: Magnetic resonance imaging;
NRS: Numeric rating scale; NTX-I: N-terminal telopeptide of collagen type I;
OA: Osteoarthritis; OC: Osteocalcin; PIIANP: N-terminal propeptide of
procollagen type IIA; PIIINP: N-terminal propeptide of procollagen type III;
PINP: N-terminal propeptide of procollagen type I; QUIPS: Quality in
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WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index;
YKL-40: Cartilage glycoprotein 40; YMN: Yearly mean narrowing
Table 6 Overview of factors with strong evidence to be predictive of progression, overlap and differences between this review and
the review of de Rooij et al., Wright et al., and Lievense et al.
Prognostic factor Teirlinck et al. factor predictive of De Rooij et al. factor predictive of Wright et al.
factor
predictive of
Lievense et al.
factor
predictive of
K-L grade at
baseline
THR Strong evidence for no association for
clinical progression
Radiological
progression
or THR*
Not mentioned
Subchondral
sclerosis at baseline
THR Not mentioned Radiological
progression
and/or THR
Not mentioned
Superior or (supero)
lateral femoral head
migration
THR Not mentioned Radiological
progression
and/or THR
Radiological
progression
and/or THR
Comorbidity Clinical progression Clinical progression (strong evidence
for a course of function, weak
evidence for a course of pain)
Not mentioned Not mentioned
Low vitality Quality of life in general: strong evidence of no
association, specific for SF 36 vitality: strong
evidence for clinical progression
Course of function Not mentioned Not mentioned
Age Conflicted evidence for THR and radiological
progression, moderate evidence for no
association with clinical progression
Strong evidence for no association with
pain and conflicted evidence for function
Radiological
progression
and/or THR
Conflicted
evidence
Femoral
osteophytes
Conflicted evidence Not mentioned Radiological
progression
and/or THR
Not mentioned
Hip pain at baseline Conflicted evidence Conflicted evidence Radiological
progression
and THR
Not mentioned
JSW at baseline Conflicted evidence Not mentioned Radiological
progression
and/or THR
Limited
evidence for
THR
Lequesne index
score ≥ 10 at
baseline
Conflicted evidence for THR, moderate evidence
for radiological progression**
Conflicted evidence** Radiological
progression
and/or THR
Not mentioned
Atrophic bone
response
Conflicted evidence Not mentioned Conflicted
evidence
Radiological
progression
*K-L grade 3 at baseline
**Function at baseline in general
bold text represents strong evidence to be predictive of progression
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